MedTrace Logo

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

NCT03809663 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 251

Last updated 2022-03-10

Study results available
· View outcomes & findings →

Summary

This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe atopic dermatitis (AD).

Conditions

Interventions

DRUG

Tezepelumab

Solution for injection

OTHER

Placebo

Placebo solution for injection

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-15
Primary Completion
2020-05-12
Completion
2020-12-22
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Czechia
  • Estonia
  • Germany
  • Hungary
  • Japan
  • Latvia
  • Poland
  • South Korea
  • Spain
  • Switzerland
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03809663 on ClinicalTrials.gov